Breakthrough Discovery Identifies Key Protein Driving Common Tendon Injuries
A new study pinpoints the HIF1 protein as a central trigger for tendinopathies – conditions like Achilles tendon pain, tennis elbow, swimmer’s shoulder, and jumper’s knee – offering hope for more effective treatments beyond physical therapy.
These debilitating conditions, affecting both elite athletes and everyday individuals, arise when tendons are repeatedly strained and pushed beyond their natural limits. “Tendons are fundamentally susceptible to overuse,” explains a professor of orthopaedic biomechanics at ETH Zurich and Balgrist University Hospital in Zurich. “They must withstand powerful loads, with all the forces of our muscles being concentrated to the relatively thin tendons that transmit these forces into movement of our skeleton.”
Understanding Tendinopathies: A Common, Yet Challenging Problem
Doctors classify these disorders as tendinopathies, a broad term encompassing tendon pain and dysfunction. They represent some of the most frequently treated issues by orthopedic specialists, yet current therapies often fall short. While physical therapy can provide relief, it frequently offers only modest improvement, prompting researchers to seek a deeper understanding of the underlying causes of tendon disease.
HIF1 Protein Identified as a Molecular Cause
A research team, led by scientists at ETH Zurich, has now made a significant leap forward. They’ve identified a protein called HIF1 as a key driver of these conditions. HIF1 functions as a transcription factor, meaning it regulates the activity of specific genes within cells. Previous research had noted elevated levels of HIF1 in damaged tendons, but its precise role remained unclear.
Through meticulous experiments involving mice and analysis of human tendon tissue, the team definitively demonstrated that HIF1 isn’t merely associated with tendon disease – it actively triggers it.
Experiments Reveal a Direct Link to Tendon Damage
The research team’s mouse studies were particularly revealing. Mice with permanently activated HIF1 developed tendon disease even without experiencing excessive strain. Conversely, mice where HIF1 was deactivated in tendon tissue remained healthy, even when their tendons were deliberately overloaded.
Further investigation of human tendon cells collected during surgeries confirmed these findings. In both mouse and human samples, higher levels of HIF1 correlated with harmful structural changes within the tendons. Specifically, the researchers observed an increase in crosslinks forming within the collagen fibers – the very components that provide tendons with their strength and structure.
“This makes the tendons more brittle and impairs their mechanical function,” explains a doctoral student involved in the study. The team also noted increased growth of blood vessels and nerves into the tendon tissue, potentially explaining the pain commonly experienced by those with tendinopathy.
The Importance of Early Intervention
“Our study not only provides new insight into how the disease develops, it also shows that it’s important to treat tendon problems early,” says a senior researcher on the project. Young athletes are particularly vulnerable, often experiencing tendinopathies while their condition remains potentially manageable.
However, the damage linked to HIF1 can accumulate over time, eventually becoming irreversible. “The damage caused by HIF1 in tendon tissue can accumulate and become irreversible over time. Physiotherapy then no longer helps, and the only treatment at this moment is to surgically remove the diseased tendon,” the researcher cautioned.
The Future of Tendon Treatment: Targeting HIF1
With HIF1 now identified as a central molecular driver of tendon disease, the question naturally arises: can drugs be developed to block its activity and prevent or reverse tendinopathy?
The answer, according to researchers, is complex. HIF1 plays a vital role throughout the body, sensing low oxygen levels (hypoxia) and triggering normal adaptive responses. Completely shutting down HIF1 systemically could lead to significant side effects.
A more promising strategy, researchers believe, lies in finding ways to specifically reduce HIF1 activity only within tendon tissue. Alternatively, a deeper investigation into the biological processes surrounding HIF1 could reveal other, safer targets for treating tendinopathy. That crucial search is already underway.
